PRGO - Perrigo responds to 'misleading and inaccurate information' on Zantac claims

• Perrigo ( NYSE: PRGO ) Wednesday afternoon said that an August 16 notice of dismissal of claims and impending trial against the branded companies that manufactured Zantac (ranitidine) did not involve the company .
• Perrigo said that contrary to a news report, the plaintiff's complaint in the case states the purchase of both brand name Zantac and private label -- generic -- ranitidine.
• The company added that scientific evidence demonstrates there is no causal relationship between ranitidine and cancer.
• Also, Perrigo has certain protections under the principle of federal preemption, which it has used successfully in many cases.
• Zantac was withdrawn from the market in 2020 due to concerns that the drug was linked to u nacceptable levels of potential human carcinogen, N-nitrosodimethylamine (NDMA) .

For further details see: